Study of LP-184 in Patients With Advanced Solid Tumors

Summary

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Timeline

Start

2023-06-09

Primary completion

2026-07-28

Completion

2026-07-28

Outcome

Met primary endpoint

release “today announced the successful completion of its Phase 1a clinical trial (NCT05933265) for LP-184. The trial met all primary endpoints” lanternpharma.com ↗

release “The Phase 1a trial (NCT05933265), which enrolled 63 patients, achieved all primary endpoints” lanternpharma.com ↗

release “LP-184 completed a 63-patient Phase 1a trial (NCT05933265) achieving all primary endpoints” lanternpharma.com ↗

Publications

• Mahadevan D, Parekh J, Beck JT, McKean WB Jr, Schreck KC, Olszanski AJ, Shields MD, Phan V, Hamm JT, Bank BB, Zhou J, Chamberlain M, Bhatia K, Ewesuedo R. A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors. Invest New Drugs. 2026 Jul 7. doi: 10.1007/s10637-026-01626-y. Online ahead of print.

Drugs

Indications